Paste your Google Webmaster Tools verification code here
Read in this issue, why Daiichi Sankyo, the Japanese firm had to offload Ranbaxy which it had acquired eight years back with a hope to expand its business and secure its position in the world market even after the patent expiry of it's most famous drugs. Grab your copy to find out more!
Biotecnika bureau had a chance to interact with Ms. Anu Acharya, CEO, Mapmygenome on her entrepreneurial voyage and Dr. Anurag Mathur, Lead author, “Heart-on-chip” on his recent research.
Also read in the issue:
The Indian biotech sector faced a major turn of events when Daiichi Sankyo, Japanese firm whose hide and seek with Indian drug company Ranbaxy came to an end as it decided to sell off its entire holding of Sun Pharmaceutical Industries and exit Indian pharma sector after a struggle of eight years. Why it had to offload Ranbaxy and what is in store with the company’s future businesses, find out in Biotecnika magazine’s May 2015 issue.
2014 Powered By Wordpress, Goodnews Theme By Momizat Team